DUL:ETR
Alnylam Pharmaceuticals, Inc.
€199.75
arrow_downward
-1.21%(-2.45) 1D
Okt 15, 9:04:32 AM GMT+2 · EUR
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa DUL...
Buksan
€199.75
Mataas
€199.75
Mababa
€199.75
Mkt. cap
30.04B
Avg. na dami
38.00
Dami
0.00
Mataas nang 52-wk
€417.40
Mababa nang 52-wk
€177.10
Bilang ng mga empleyado
2K
Buksan
€199.75
Mataas
€199.75
Mababa
€199.75
Mkt. cap
30.04B
Avg. na dami
38.00
Dami
0.00
Mataas nang 52-wk
€417.40
Mababa nang 52-wk
€177.10
Bilang ng mga empleyado
2K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
BioSpace
·
1 araw ang nakalipas
Alnylam bulls and bears fight it out after business-shaking guidance cut
The Globe and Mail
·
2 linggo ang nakalipas
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Tungkol sa Alnylam Pharmaceuticals, Inc.